Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical and molecular significance of the RNA m6A methyltransferase complex in prostate cancer

ABSTRACT: shRNAs targeting METTL3 used to deplete METTL3 in castrate-resistant LNCaP:C42 prostate cancer cells and the effect on gene expression and splicing determined.

ORGANISM(S): Homo sapiens

PROVIDER: GSE210130 | GEO | 2023/01/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The METTL3 RNA methyltransferase regulates androgen signalling in castrate resistant prostate cancer cells

Project description:siRNAs targeting METTL3 used to deplete METTL3 in castrate resistant LNCaP:C42 and 22Rv1 prosate cancer cells and the effect on basal and androgen regulated gene expression and splicing determined.

2022-11-02 | GSE194420 | GEO

Exploring the Impact of m6A Methyltransferase Mettl3 on MASLD through Multi-Omics Analysis

Project description:Background: N6-methyladenosine (m6A) RNA modification plays a crucial role in various biological events and is implicated in various metabolic-related diseases. However, its role in MASLD remains unclear. This study aims to investigate the impact of Mettl3 on MASLD through multi-omics analysis, with a focus on exploring its potential mechanisms of action. Methods: MASLD mouse models were established by feeding a high-fat diet for 12 weeks, and Mettl3 stable overexpression AML12 cell models were constructed via lentiviral transfection. Subsequent transcriptomic and proteomic analyses, as well as integrated analysis between different omics datasets, were conducted. Results: Mettl3 expression significantly increased in MASLD mouse models. In the transcriptomic and proteomic analyses, we identified 848 genes with significant inconsistencies between transcriptomic and proteomic datasets. GO/KEGG enrichment terms may involve post-transcriptional modifications, particularly Mettl3-mediated m6A modification. Subsequently, through integrated proteomic analysis of Mettl3-overexpressed AML12 cell models and MASLD mouse models, we selected the top 20 co-upregulated and co-downregulated GO/KEGG terms as the main biological processes influenced by Mettl3 in MASLD. By intersecting with pathways obtained from previous integrated analyses, we identified GO/KEGG terms affected by Mettl3-induced m6A modification. Protein-protein interaction analysis of proteins involved in these pathways highlighted GAPDH, ENO1, and TPI1 as three key hub genes. Conclusion: In MASLD, Mettl3 regulates the glycolytic pathway through m6A modification, influencing the occurrence and development of the disease via the key hub genes GAPDH, ENO1, and TPI1. These findings expand our understanding of MASLD and provide strong evidence for potential therapeutic targets and drug development.

2024-09-20 | PXD050565 | Pride

The METTL3 RNA methyltransferase regulates estrogen signalling in MCF-7 breast cancer cells

Project description:siRNAs targeting METTL3 were used to deplete METTL3 in MCF-7 breast cancer cells and the effect on basal and estrogen regulated gene expression determined.

2025-11-30 | GSE195532 | GEO

The METTL3:METTL14 RNA methyltransferase regulates gene expression in MDA-MB-231 breast cancer cells

Project description:siRNAs targeting METTL3 and METTL14 were used to deplete METTL3 and METTL14 in MDA-MB-231 breast cancer cells and the effects on gene expression determined.

2025-11-30 | GSE234571 | GEO

A Cleavage Product METTL3a-(238-580) Mediates m6A Methyltransferase Complex Assembly and mTOR Activation

Project description:N6-methyladenosine (m6A) methylation of mRNA by the methyltransferase complex (MTC), with core components including METTL3-METTL14 heterodimers and Wilms’ tumor 1-associated protein (WTAP), contributes to breast tumorigenesis, but the mechanism of MTC assembly remains elusive. Here, we identify a novel cleaved form METTL3a (residues 239-580 of METTL3), that is highly expressed in breast cancer. Furthermore, we find that both METTL3a and full-length METTL3 are required for MTC assembly, RNA m6A deposition, as well as cancer cell proliferation. Mechanistically, we find that METTL3a is required for METTL3-METTL3 interaction, which is a prerequisite step for recruitment of WTAP in MTC assembly. Analysis of m6A sequencing data shows that depletion of METTL3a globally disrupts m6A methylation, and METTL3a mediates mTOR activation via m6A-mediated suppression of TMEM127 expression. Consequently, we find that METTL3 cleavage is mediated by proteasome in an mTOR-dependent manner, revealing positive regulatory feedback between METTL3a and mTOR signaling. Our findings reveal METTL3a as an important component for MTC assembly, and suggest the METTL3a-mTOR axis as a potential therapeutic target for breast cancer.

2023-08-16 | GSE213727 | GEO

The METTL3 RNA methyltransferase regulates gene expression in castrate resistant LNCaP:C42 prostate cancer cells

Project description:The METTL3 RNA methyltransferase regulates gene expression in castrate resistant LNCaP:C42 prostate cancer cells

| PRJNA801594 | ENA

m6A-seq profiling in Mettl3 Ctrl and dTAG13 mESCs [m6Aseq]

Project description:dTAG-13 treated METTL3_FKBP12(F36V) is sufficient to functionally deplete m6A methylation, that catalysed by METTL3/14 complex.

2020-09-15 | GSE154707 | GEO

m6A-seq profiling in Mettl3 Ctrl and dTAG-13 treated mESCs

Project description:dTAG-13 treated METTL3_FKBP12(F36V) is sufficient to functionally deplete m6A methylation catalysed by METTL3/14 complex.

2025-06-19 | GSE297888 | GEO

The role of CBLL1 (HAKAI) component of the RNA methyltransferase complex in androgen signaling in breast cancer cells (MDA-MB-231)

Project description:CBLL1, also known as HAKAI, plays a dual role in the METTL3-containing RNA m6A methyltransferase complex and as a regulator of e-cadherin protein expression. RNA methylation is known to play diverse functions in the regulation of mRNA processing, splicing, translation and stability. In this study we used siRNA to deplete CBLL1 in the MDA-MB-231 triple negative breast cancer cell line and the effect on global transcription determined.

2025-11-30 | GSE271330 | GEO

The role of CBLL1 (HAKAI) component of the RNA methyltransferase complex in basal and estrogen signaling in breast cancer cells (MCF-7)

Project description:CBLL1, also known as HAKAI, plays a dual role in the METTL3-containing RNA m6A methyltransferase complex and as a regulator of e-cadherin protein expression. RNA methylation is known to play diverse functions in the regulation of mRNA processing, splicing, translation and stability. In this study we used siRNA to deplete CBLL1 in the MCF-7 breast cancer cell line and determined the effect on basal and estrogen regulated transcription

2025-11-30 | GSE271326 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data